Moderna and Merck's mRNA cancer vaccine cuts death or recurrence by 42%
Health Tech·October 23, 2026

Moderna and Merck have now published the top-line numbers from their late-stage trial of an mRNA cancer vaccine, putting figures behind a success the companies had flagged earlier. The headline result is a 42 percent reduction in the combined risk of death or cancer recurrence compared with the trial's comparison group.
The vaccine is built around the same mRNA platform that powered Moderna's COVID-19 shots, but it works differently. Rather than protecting against a virus, it is designed for each patient, using genetic markers drawn from that person's own tumor to train the immune system to recognize and attack cancer cells. That personalization is what makes the approach harder to manufacture and test than a standard vaccine, which is part of why results like these are being watched so closely across the industry.
The announcement is a top-line summary, so it leaves important questions open. It does not give a full breakdown of survival data, the size of the effect across different patient groups, or the side-effect profile in detail. Those details typically come later, usually through a scientific conference presentation or a peer-reviewed paper, and independent researchers will want to see them before drawing firm conclusions.
Still, a 42 percent reduction is a strong signal for a field that has long struggled to show clear benefits from cancer vaccines in large trials. If the findings hold up in the full data, they would give Moderna and Merck a much stronger case with regulators and could shape how the mRNA platform is used beyond infectious disease.
Reporting based on an external source.